Talabostat is under clinical development by BioXcel Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Talabostat’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Talabostat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Talabostat is under development for the treatment of metastatic castration resistant small cell neuroendocrine prostate cancer (NEPC), metastatic melanoma, metastatic pancreatic ductal adenocarcinoma, acute myelogenous leukemia (AML) and advanced solid cancers. It is administered orally. It targets dipeptidyl peptidase 8 and 9.
It was also under development for the treatment of non-small cell lung cancer, metastatic adenocarcinoma of the pancreas, metastatic melanoma, chronic lymphocytic leukemia and relapsed or refractory solid tumors including brain tumors.
BioXcel Therapeutics overview
BioXcel Therapeutics is a commercial-stage biopharmaceutical company focused on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology. Its pipeline product portfolio comprises BXCL501, an adrenergic agent with a sublingual route of administration is used for treating neuropsychiatric and neurodegenerative diseases; BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers; and BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders. The company’s drug re-innovation approach leverages existing approved drugs and clinically validated product candidates with big data and proprietary machine learning algorithms to develop new therapeutic candidates. BioXcel Therapeutics is headquartered in New Haven, Connecticut, the US.
Quick View Talabostat LOA Data
|Highest Development Stage|